Paraxanthine has entered the conversation. A handful of new brands are marketing it as "the next evolution of caffeine" — a cleaner, smarter, jitter-free stimulant that makes regular caffeine look like a relic. The pitch is compelling. But what does the peer-reviewed science actually say?
We went through the published research — not marketing decks, not influencer posts, the actual studies — to give you an honest comparison of paraxanthine vs. caffeine. No agenda. Just data.
What Is Paraxanthine?
Paraxanthine (1,7-dimethylxanthine) is the primary metabolite of caffeine. When you drink coffee, your liver converts approximately 80% of the caffeine into paraxanthine via the CYP1A2 enzyme. The remaining 20% is converted into theobromine and theophylline.
In other words, your body already produces paraxanthine every time you drink coffee. It's not a new molecule — it's what caffeine becomes after your liver processes it.
The premise behind supplemental paraxanthine is: why not skip the middleman? Instead of consuming caffeine and waiting for your liver to convert it, just take paraxanthine directly. Proponents argue this produces a "cleaner" stimulant effect with fewer side effects.
It's a logical hypothesis. But hypotheses require evidence.
The Published Evidence: What We Actually Know
The Safety Study (PMC9932512)
The most-cited paraxanthine safety study was published in Frontiers in Toxicology in February 2023 by Szlapinski et al. Here's what it actually tested:
Study design: Preclinical toxicology battery in Sprague Dawley rats. This included genotoxicity assays (Ames test, chromosomal aberration), acute oral toxicity, and a 90-day repeated dose study.
Key findings:
- No mutagenicity or genetic toxicity detected in vitro
- Acute oral LD50 of 829 mg/kg for paraxanthine vs. 127-367 mg/kg for caffeine (paraxanthine showed a wider safety margin in rats)
- 90-day NOAEL (no observed adverse effect level) of 185 mg/kg for paraxanthine vs. 150 mg/kg for caffeine
- Two deaths occurred in the high-dose caffeine group; zero in the paraxanthine group
Critical context the marketing leaves out:
This was entirely a rodent study. The concluding language reflects this: the authors wrote that these findings "may suggest" that paraxanthine "could be" a safer alternative. That's appropriate scientific hedging for animal data that hasn't been replicated in humans.
Additionally, the paraxanthine tested in this study was supplied by the ingredient manufacturer. The study authors disclosed affiliations with the company commercializing paraxanthine as a supplement ingredient. This doesn't invalidate the research, but it's relevant context when evaluating marketing claims built on top of it.
The Clinical Trial (NCT06628596)
A human clinical trial titled "Acute Effects of Paraxanthine on Energy, Focus, Appetite, and Cognition" was conducted in 2024, sponsored by Iovate Health Sciences International.
Study design: Double-blind, placebo-controlled, crossover. Tested 200mg and 300mg paraxanthine doses.
Status: Completed (May-August 2024). As of mid-2026, no peer-reviewed results have been published from this trial.
Key limitation: This is an acute (single-dose) study. It tells us nothing about chronic use, long-term safety, tolerance development, or withdrawal effects. For a compound being marketed as a daily caffeine replacement, the absence of long-term data is significant.
Other Human Data
A small number of additional human trials exist, testing paraxanthine's acute effects on reaction time, attention, and memory at doses of 100-200mg. These are small crossover studies showing modest cognitive benefits — similar in magnitude to what caffeine itself produces at equivalent doses.
Critically, there are zero published human trials on physical performance — no endurance data, no strength data, no power output data in humans. The performance claims you'll find in marketing materials ("39% treadmill improvement," "17% grip strength increase") trace back to the single rodent study. Rat treadmill performance does not reliably predict human athletic outcomes.
The Dose Problem
This is where the paraxanthine pitch runs into practical reality.
Most paraxanthine-based products deliver 60mg per serving. That's the standard dose in the leading paraxanthine cold brew product. Compare this to the caffeine content in established cold brews:
| Stimulant Source | Amount per Serving | Type |
|---|---|---|
| Paraxanthine cold brew | 60mg | Synthetic paraxanthine added to decaf |
| Naturally brewed cold brew | 320mg | Natural caffeine from extraction |
| Standard drip coffee | 95-165mg | Natural caffeine from brewing |
| Espresso (double shot) | 125-150mg | Natural caffeine from extraction |
Even if we accept the argument that paraxanthine is "more efficient" than caffeine milligram-for-milligram, the dose gap is enormous. You'd need to consume roughly 5 servings of a 60mg paraxanthine product to match the stimulant load of a single 320mg cold brew — and even then, the comparison assumes a 1:1 potency equivalence that hasn't been established in human dose-response studies.
The human cognitive trials that showed positive results used 200mg doses — more than 3x what most commercial paraxanthine products contain. At 60mg, you're below the threshold where the compound has demonstrated measurable effects in the studies its proponents cite.
The "Decaf + Supplement" Model vs. Real Cold Brew
Paraxanthine cold brew products start with decaffeinated coffee, then add synthetic paraxanthine back in. This creates a fundamentally different product than naturally brewed cold brew:
Decaffeination removes more than caffeine. The decaffeination process (whether Swiss Water, CO2, or solvent-based) extracts other bioactive compounds alongside the caffeine. Chlorogenic acids, which researchers have studied for their antioxidant activity, are partially removed during decaffeination. The resulting base coffee has a different chemical profile than regular coffee.
You lose the entourage effect. The associations researchers have reported for coffee come from studies of whole coffee, not of isolated caffeine — so it isn't obvious those findings carry over to a decaf base with a single synthetic metabolite added back in. Caffeine is one player in a complex orchestra.
Your body already does the conversion. Your liver converts 80% of caffeine into paraxanthine naturally, at a rate governed by your individual CYP1A2 enzyme activity. That staged conversion is one proposed explanation for why coffee's effects tend to spread over hours, though it has not been tested head-to-head against supplemental paraxanthine in humans. Bypassing this natural metabolism doesn't obviously improve the experience.
The Evidence Gap: Caffeine vs. Paraxanthine
The asymmetry in the evidence base is staggering:
| Metric | Caffeine | Paraxanthine |
|---|---|---|
| Years of documented human use | 500+ years | <5 years as supplement |
| Published human studies | Thousands | Fewer than 10 |
| Long-term safety data in humans | Extensive (decades) | None published |
| FDA daily limit guidance | 400mg/day for healthy adults | None established |
| Human performance studies | Hundreds (endurance, strength, power) | Zero published |
| Epidemiological data | Large-scale observational studies (millions of subjects) | None |
| GRAS status | FDA-reviewed and established | Self-affirmed (not FDA-reviewed) |
This doesn't mean paraxanthine is dangerous. It means we don't know enough to make confident claims about its long-term safety or superiority. And "we don't know yet" is a very different statement than "it's better."
The Cost Equation
There's also a practical dimension. Paraxanthine cold brew products typically retail at $5 per can for 60mg of the compound. That's approximately $0.08 per milligram of stimulant.
A naturally brewed cold brew delivering 320mg of caffeine at $4.50 per can costs approximately $0.014 per milligram. That's roughly a 6x premium for paraxanthine on a per-milligram basis — for a compound with a fraction of the evidence base.
What the Science Actually Supports
Based on the current state of published, peer-reviewed research:
Caffeine from coffee is the most extensively studied stimulant in human history. Its safety profile, effective dosing ranges, performance benefits, and metabolic effects are supported by thousands of studies across millions of subjects.
Paraxanthine shows promise in preclinical models and a small number of acute human studies. It may offer a somewhat different side-effect profile than caffeine at equivalent doses. But the evidence base is in its infancy, and the commercial products available deliver doses well below what the existing studies tested.
Cold brew extraction produces a complete package — caffeine plus the full spectrum of coffee's bioactive compounds, delivered at a concentration in the range the performance literature has studied. The "decaf + supplement" model strips this package apart and reassembles it with a single synthetic component.
We'll be watching the paraxanthine research with interest. More human trials are needed, and the results may eventually support stronger claims. But science moves at the speed of evidence, not marketing. And right now, the deeper evidence base belongs to what humans have relied on for centuries: natural caffeine from coffee.
Bare Brew is cold brew coffee with two ingredients: Honduran Arabica coffee and filtered water. 320mg of natural caffeine per can. 0g sugar. 20 calories. Your liver handles the paraxanthine conversion — it's been doing it since your first cup.
